BlueMatrix and Perplexity Partner to Bring AI-Powered Discovery to Institutional Research
13.1.2026 13:00:00 EET | Business Wire | Press release
BlueMatrix, the global leader in capital markets content publishing technology, backed by Thoma Bravo, today announced a partnership with Perplexity to bring AI-enabled research and discovery to institutional investors using BlueMatrix’s governed, entitlement-aware framework.
The partnership brings entitled broker research to Perplexity Enterprise users, enabling buy-side professionals to query their subscribed research content, alongside Perplexity’s broader capabilities, including real-time financial data, earnings transcripts, and deep research tools. Investment professionals and researchers can use natural language to surface relevant insights without changing existing data ownership, entitlements, or compliance structures.
As buy-side teams increasingly turn to AI tools for research synthesis, a formal integration through BlueMatrix replaces unstructured, ungoverned usage with compliant distribution that preserves attribution and entitlements. For research firms, the partnership provides a new channel to increase visibility with buy-side clients, gaining presence within an AI-powered discovery experience while maintaining full control over their content. Research providers also gain new insight into how investors interact with their analysis, the types of questions they’re asking most, and how they’re integrating those results into their AI-assisted workflows.
BlueMatrix provisions access on behalf of research providers, ensuring that only clients with existing agreements can surface a firm’s content. Proprietary research remains fully protected and is never used to train AI models or leave institutional boundaries.
“At BlueMatrix, our priority is to help clients benefit from AI while preserving attributions, control, and flexibility,” said Patricia Horotan, CEO of BlueMatrix. “This new partnership with Perplexity delivers AI-assisted discovery to investors and researchers, alongside Perplexity’s suite of accuracy-driven research tools. For research providers, it offers a new way to ensure that their insights reach clients at the moment of decision, without compromising the governance and data-first, model-neutral strategy they expect from BlueMatrix.”
“BlueMatrix is a clear leader in capital markets technology, and we’re excited to align AI innovation with the strict governance standards financial institutions and researchers require,” said Dmitry Shevelenko, Chief Business Officer at Perplexity. “This partnership demonstrates how AI-powered search can enhance access to entitled research content, and help investment professionals move from question to insight and insight to decisions faster.”
During the initial pilot phase of the partnership, a limited group of early-adopter firms will explore AI-assisted workflows that allow buy-side professionals to ask natural-language questions, such as “What are my brokers saying about this issuer following earnings?”, and receive cited responses grounded in the entitled research they already receive via BlueMatrix and Perplexity’s broader suite of Enterprise data sources.
Use cases will include issuer monitoring, post-earnings and event follow-up, and thematic research. BlueMatrix serves as the secure system of record for research authoring, compliance, and entitlements, while Perplexity Enterprise provides the AI-powered interface for deep research. A private beta will follow integration and security reviews, with feedback from participating firms shaping future features, including expanded entitlement scenarios, deeper use of metadata such as RIXML, and enhanced engagement reporting.
About BlueMatrix
BlueMatrix is the global leader in capital markets content publishing technology, trusted by over 1,000 financial institutions. Its secure platform streamlines authoring, compliance, and distribution—driving smarter, faster collaboration across capital markets. Founded in 1999 and backed by Thoma Bravo, BlueMatrix operates from offices in Durham (HQ), New York, London, Paris, Edinburgh, Auckland, and Timisoara.
About Perplexity
Perplexity is an AI-powered answer engine that draws from credible sources in real time to accurately answer questions with in-line citations, perform deep research, and more. Perplexity Enterprise provides secure, organization-aware access to AI-assisted research workflows that integrate proprietary data with trusted public sources. Founded in 2022, the company's mission is to serve the world's curiosity by bridging the gap between traditional search engines and AI-driven interfaces. Each week, Perplexity answers more than 150 million questions globally. Perplexity is available in the app store and online at:
View source version on businesswire.com: https://www.businesswire.com/news/home/20260113633321/en/
Contacts
Media Inquiries:
Emily O’Brien
emily@getepic.io
BlueMatrix/Perplexity Inquiries:
https://www.bluematrix.com/www3/RequestInformation.action -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.bluematrix
.com%2Fwww3%2FRequestInformation.action&esheet=54395104&newsitemid=2026011363332
1&lan=en-US&anchor=https%3A%2F%2Fwww.bluematrix.com%2Fwww3%2FRequestInformation.
action&index=3&md5=a302ac3671efdca847406350dbf660e9sales@bluematrix.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Initiates Phase I Clinical Trial in Australia Evaluating ME3241, an Anti-PD-1 Agonist Antibody Discovered Through Collaborative Research With FBRI12.3.2026 08:00:00 EET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) announced today that it has initiated a Phase I clinical trial of ME3241 (development code), an anti-PD-1 agonist monoclonal antibody discovered through collaborative research with the Foundation for Biomedical Research and Innovation at Kobe (Headquarters: Kobe, Japan; President: Shuh Narumiya; hereinafter “FBRI”). The Phase I clinical trial is designed as a randomized, placebo-controlled, double-blind study, with the objective of evaluating the safety and tolerability of ME3241 following single and multiple dosing, as well as its pharmacokinetics and pharmacodynamics (ClinicalTrials.gov: NCT07422207). ME3241 was discovered through a collaborative research program led by Program Director Tasuku Honjo, a professor emeritus at Kyoto University. PD-1 is a molecule expressed on activated T cells and other lymphocytes that suppresses immune responses. Through this re
Redslim expands into Asia-Pacific to support global brands with data and AI infrastructure12.3.2026 08:00:00 EET | Press release
Redslim, a specialist in end-to-end data management solutions and an Astorg portfolio company, today announced its expansion into the Asia-Pacific region and the appointment of Kyriakos Zannikos as Regional Director, APAC. The move marks an important milestone in Redslim’s global growth strategy and brings the company closer to clients operating in one of the world’s fastest-growing and most data-driven consumer markets. As global consumer brands accelerate digital transformation and AI adoption, many organizations still struggle with fragmented data ecosystems spanning multiple agencies, markets and datasets. These challenges are particularly pronounced in Asia-Pacific, where diverse market structures and rapid growth create complex data environments. Redslim helps organizations transform fragmented market information into valuable data assets, empowering clients to make confident decisions and unlock the full value of their data. By building strong data foundations, Redslim supports
EIG’s MidOcean Energy to Acquire Additional Gorgon LNG Interest from JERA; Parties Explore Strategic Alliance12.3.2026 04:14:00 EET | Press release
MidOcean Energy (“MidOcean”), a liquefied natural gas (LNG) company formed and managed by EIG, today announced it has entered into definitive agreements with JERA Co., Inc. (“JERA”) to acquire JERA Gorgon Pty Ltd, which holds JERA’s 0.417% interest in the Gorgon LNG project. MidOcean is an existing participant in the Gorgon LNG project, and this transaction increases MidOcean’s interest in Gorgon to 1.417%. The transaction perimeter also includes JERA’s 0.735% interest in the Ichthys LNG project. Subject to the satisfaction of relevant conditions precedent, the interests in Gorgon and Ichthys will be sold to MidOcean, and then the Ichthys interest shall be transferred, subject to the satisfaction of further conditions, to an existing joint venture participant in the Ichthys LNG project. The acquisition increases MidOcean’s equity exposure to a large-scale, long-life, integrated LNG project operated by Chevron, further strengthening its portfolio of high-quality producing assets. In par
DCX Launches Comprehensive ECDU Portfolio – Enterprise-Class Coolant Distribution Units From 600 kW to 2.6 MW11.3.2026 17:34:00 EET | Press release
DCX Liquid Cooling Systems today unveiled its new ECDU (Enterprise Coolant Distribution Unit) platform, a family of three purpose-built CDU models that deliver real cooling capacities from 600 kW to 2.6 MW in industry-standard rack and in-row footprints. The portfolio has been engineered specifically for the accelerating transition to direct-to-chip liquid cooling in high-density enterprise, colocation, cloud, and hyperscale AI environments where thermal stability, uptime, and cost-efficiency are non-negotiable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311214891/en/ DCX ECDU, the new generation of Enterprise Coolant Distribution Units dedicated to HPC and AI deployments. The lineup consists of: Enterprise ECDU 1380/2600 V1 - Delivers 1.38–2.6 MW of actual cooling capacity (based on real-world secondary-loop conditions). Single-pump configuration reaches flow rates up to 3,333 liters per minute (lpm). Mission Critica
Laserfiche Earns 5-Star Rating in the 2026 CRN® Partner Program Guide11.3.2026 16:00:00 EET | Press release
Laserfiche — the leading SaaS provider of intelligent content management — has been honored by CRN®, a brand of The Channel Company, with a 5-Star Award in the 2026 CRN Partner Program Guide. This annual guide is an essential resource for partners seeking vendor partner programs that match their business goals and deliver high partner value. As organizations navigate growing pressure to increase productivity and respond to regulatory change, Laserfiche’s AI-powered document management solutions enable users to transform operations and achieve meaningful business results at scale. Partners that innovate with Laserfiche solutions have the opportunity to grow profits through the Laserfiche Partner Program, which equips them with the tools and resources needed to deliver customer success. Laserfiche’s partner ecosystem drives sustainable growth, delivers differentiated solutions and maximizes opportunities for both partners and their customers. Laserfiche provides comprehensive AI and clou
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom